Stereotaxis Inc (A:STXS)

Business Focus: Advanced Medical Equipment & Technology

Apr 22, 2024 07:51 am ET
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of...
Mar 04, 2024 04:06 pm ET
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulatory submissions were made recently in both Europe and the United States for the MAGiC™...
Mar 04, 2024 04:05 pm ET
Stereotaxis Reports 2023 Full Year Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. “We enter 2024 having made...
Feb 22, 2024 04:15 pm ET
Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation (RMN) system at Intermountain...
Feb 20, 2024 09:05 am ET
Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on...
Jan 08, 2024 08:34 am ET
Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC™....
Nov 28, 2023 08:42 am ET
Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, and Baptist Health Lexington, a leading health provider in Kentucky, today announced that physicians have built upon their two-decades of...
Nov 20, 2023 08:54 am ET
Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 35th Annual Healthcare...
Nov 09, 2023 09:00 am ET
Stereotaxis Reports 2023 Third Quarter Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2023. “Stereotaxis continues to deliver...
Oct 31, 2023 08:57 am ET
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP...
Oct 17, 2023 09:05 am ET
Stereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, 2023 before the...
Oct 04, 2023 08:49 am ET
Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s 7th Annual Meeting, which will...
Sep 06, 2023 08:56 am ET
Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Heart Centre Rigshospitalet of Copenhagen University Hospital successfully treated the...
Aug 30, 2023 08:49 am ET
Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Overland Park Regional Medical Center (OPRMC) launched and successfully completed the...
Aug 16, 2023 08:40 am ET
Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming...
Aug 10, 2023 09:00 am ET
Stereotaxis Reports 2023 Second Quarter Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2023. “Stereotaxis delivered 28% revenue growth in...
Jul 18, 2023 09:18 am ET
Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients have been successfully treated utilizing Abbott’s EnSite™ X EP System with Stereotaxis’...
Jul 17, 2023 06:00 am ET
Stereotaxis to Report Second Quarter 2023 Financial Results on August 10, 2023
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 second quarter on Thursday, August 10, 2023 before the...
Jun 15, 2023 04:10 pm ET
Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intends to initiate a first-in-human trial to support the CE Mark submission for its MAGiC™...
May 25, 2023 08:56 am ET
Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in Craig-Hallum’s 20th Annual Institutional Investor...
May 23, 2023 08:46 am ET
Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic Technology
Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation (RMN) system at Advocate Christ...
May 19, 2023 08:38 am ET
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system...
May 09, 2023 09:00 am ET
Stereotaxis Reports 2023 First Quarter Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2023. “Stereotaxis continues to make significant...
Apr 18, 2023 09:05 am ET
Stereotaxis to Report First Quarter 2023 Financial Results on May 9, 2023
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 first quarter on Tuesday, May 9, 2023 before the open...
Apr 13, 2023 09:06 am ET
Over 1,000 Cardiac Patients Treated with Genesis Robotic System
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation...
Mar 20, 2023 08:08 am ET
Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort...
Mar 03, 2023 09:00 am ET
Stereotaxis Reports 2022 Full Year Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2022. “This year is poised to be...
Feb 21, 2023 09:03 am ET
Stereotaxis to Present at Cowen 43rd Annual Health Care Conference
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Cowen 43rd Annual Health Care Conference....
Feb 02, 2023 09:05 am ET
Stereotaxis to Report Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 fourth quarter and full year ended December 31, 2022 on...
Dec 20, 2022 09:04 am ET
Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System
Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of patients using the latest Genesis Robotic Magnetic Navigation (RMN) system by physicians of...
Nov 28, 2022 09:07 am ET
Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 34th Annual Healthcare...
Nov 10, 2022 09:00 am ET
Stereotaxis Reports 2022 Third Quarter Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate...
Oct 20, 2022 09:05 am ET
Stereotaxis to Report Third Quarter Financial Results on November 10, 2022
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 2022 before the...
Oct 03, 2022 09:16 am ET
Stereotaxis Receives St. Louis Mayor’s Innovation Award for 2022
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O. Jones. This...
Sep 29, 2022 09:07 am ET
International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its attendance at the Sixth Annual International Meeting of the Society for Cardiac Robotic Navigation...
Sep 13, 2022 09:06 am ET
Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the...
Aug 09, 2022 09:00 am ET
Stereotaxis Reports 2022 Second Quarter Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022. “Despite macro pressures and the poor optics...
Aug 02, 2022 09:06 am ET
Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significant enhancement of its commercial leadership team with the successful recruitment of two...
Jul 19, 2022 09:00 am ET
Stereotaxis to Report Second Quarter Financial Results on August 9, 2022
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the...
Jul 11, 2022 09:08 am ET
Stereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark submission for its MAGiC™ catheter. The MAGiC catheter is a robotically navigated magnetic...
Jun 23, 2022 08:30 am ET
Thinking about buying stock in Weber, RedHill Biopharma, Boxed, Hyzon Motors, or Stereotaxis?
NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WEBR, RDHL, BOXD, HYZN, and STXS.
Jun 06, 2022 09:07 am ET
Journal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces the publication of a special issue of the Journal of Atrial Fibrillation & Electrophysiology (JAFIB-EP) focused on...
May 10, 2022 09:00 am ET
Stereotaxis Reports 2022 First Quarter Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022. “Stereotaxis demonstrated continued progress...
May 04, 2022 09:07 am ET
Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, celebrates the achievements of the highly skilled electrophysiology team at The Heart Centre Rigshospitalet, Copenhagen...
Apr 14, 2022 09:00 am ET
Stereotaxis to Report First Quarter Financial Results on May 10, 2022
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 first quarter on Tuesday, May 10, 2022 before the open...
Mar 24, 2022 09:06 am ET
National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Poland’s National Institute of Cardiology, the leading clinical center of cardiology and cardiac surgery in...
Mar 09, 2022 09:06 am ET
Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global headquarters facility in downtown St. Louis....
Mar 03, 2022 09:00 am ET
Stereotaxis Reports 2021 Full Year Financial Results
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021. “In 2021 we delivered...
Feb 14, 2022 09:04 am ET
Stereotaxis to Present at Upcoming Investor Conferences
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, chairman and CEO, will present at three investor conferences in the first quarter 2022....
Feb 14, 2022 09:00 am ET
Stereotaxis to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2021 fourth quarter and full year ended December 31, 2021 on...
Jan 27, 2022 09:07 am ET
Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disorders in Central China
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic...
Jan 25, 2022 09:07 am ET
HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of...
Dec 08, 2021 08:03 am ET
Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Using Robotic...
Nov 18, 2021 08:05 am ET
Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include...
Nov 15, 2021 09:05 am ET
BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment
Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system,...
Nov 11, 2021 09:00 am ET
Stereotaxis Reports 2021 Third Quarter Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021. “We are proud of the progress made on...
Nov 08, 2021 09:05 am ET
Stereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Meeting
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announces it will attend the Fifth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) on...
Oct 28, 2021 09:05 am ET
Stereotaxis to Report Third Quarter 2021 Financial Results on November 11, 2021
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 third quarter on Thursday, November 11, 2021 before the...
Oct 18, 2021 07:00 am ET
First Patients Treated in Southern Europe with Stereotaxis Genesis Robotic Technology
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its Genesis Robotic Magnetic Navigation (RMN) system at Princess Grace Hospital Center in...
Oct 12, 2021 07:00 am ET
International Journal of Cardiology Publishes Data Demonstrating Superior Outcomes of Stereotaxis Robotic Cardiac Ablation in Pediatric Patients
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the International Journal of Cardiology: Heart & Vascular demonstrating superior safety and...
Sep 09, 2021 09:00 am ET
Stereotaxis to Present at Upcoming Investor Conferences
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in September 2021. Lake Street...
Aug 30, 2021 09:00 am ET
Stereotaxis and MicroPort EP Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China
Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“MicroPort EP”) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China. The agreement brings...
Aug 10, 2021 09:00 am ET
Stereotaxis Reports 2021 Second Quarter Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2021. “Renewed global adoption of robotic systems...
Jul 26, 2021 09:00 am ET
Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive...
Jul 20, 2021 09:00 am ET
Stereotaxis to Report Second Quarter 2021 Financial Results on August 10, 2021
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 second quarter on Tuesday, August 10, 2021 before the open...
May 10, 2021 09:00 am ET
Stereotaxis Reports 2021 First Quarter Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021. “The highlight of the first quarter is...
Apr 22, 2021 10:00 am ET
Kaskela Law LLC Announces Stockholder Investigation of Stereotaxis, Inc. (STXS) and Encourages Stockholders to Contact the Firm
Kaskela Law LLC announces that it is investigating Stereotaxis, Inc. (NYSE: STXS) on behalf of the company’s stockholders. The investigation seeks to determine whether Stereotaxis and/or the company’s officers and directors violated the securities...
Apr 19, 2021 09:05 am ET
Stereotaxis to Report First Quarter 2021 Financial Results on May 10, 2021
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 first quarter on Monday, May 10, 2021 before the open of...
Apr 12, 2021 09:05 am ET
Stereotaxis CEO Invited as Keynote Speaker at Robotic Surgery & Enabling Technologies Summit 2021
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that David Fischel, Chairman and CEO, will serve as the keynote speaker at the Robotic Surgery & Enabling...
Apr 07, 2021 09:00 am ET
Broward Health Medical Center Becomes First Hospital in Florida to Adopt Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medical Center is establishing a robotic electrophysiology program to expand access to advanced...
Mar 08, 2021 09:00 am ET
Stereotaxis to Establish Global Headquarters in Downtown St. Louis Globe Building
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it will move its global headquarters to the Globe Building in downtown St. Louis at the end of this year....
Feb 25, 2021 09:00 am ET
Stereotaxis Reports 2020 Full Year Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant...
Feb 24, 2021 04:05 pm ET
Stereotaxis Announces Long-Term CEO Performance Stock Award
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO performance stock award for David Fischel with vesting entirely contingent upon the company...
Feb 11, 2021 09:00 am ET
Stereotaxis to Present at Upcoming Investor Conferences
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in the first quarter 2021. BTIG...
Feb 04, 2021 09:00 am ET
Stereotaxis to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 fourth quarter and full year ended December 31, 2020 on...
Nov 09, 2020 09:00 am ET
Stereotaxis Reports 2020 Third Quarter Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020. “Stereotaxis is pleased to report revenue...
Oct 26, 2020 04:05 pm ET
Stereotaxis to Report Third Quarter 2020 Financial Results on November 9, 2020
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 third quarter on Monday, November 9, 2020 before the open...
Sep 14, 2020 09:00 am ET
First Hospitals in the World Adopt Genesis Robotic Technology for Cardiac Heart Rhythm Disorders
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has completed installations of the world’s first Genesis Robotic Magnetic Navigation (RMN) systems to treat...
Sep 08, 2020 09:05 am ET
Stereotaxis CEO Invited to Speak on Plenary Panel at RAPS Convergence 2020
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will serve as a panel speaker at the plenary session of RAPS Convergence...
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies Set to Present - this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 28, 2020 09:05 am ET
Stereotaxis to Present at Three Investor Conferences in September
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at three investor conferences in September 2020. LD Micro...
Aug 26, 2020 09:05 am ET
Journal of American College of Cardiology Publishes Pioneering Study Using Stereotaxis Robotic Technology to Treat Pulmonary Hypertension
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a pioneering publication in the prestigious Journal of the American College of Cardiology (JACC) on the use of...
Aug 06, 2020 09:00 am ET
Stereotaxis Reports 2020 Second Quarter Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2020. “Stereotaxis responded to the challenges of...
Jul 31, 2020 08:05 am ET
Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support
Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting from remote TeleRobotic Support. Dr. Gery Tomassoni of Baptist Health in Lexington, KY treated the patient utilizing integrated...
Jul 23, 2020 04:05 pm ET
Stereotaxis to Report Second Quarter 2020 Financial Results on August 6, 2020
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 second quarter on Thursday, August 6, 2020 before the open...
Jul 13, 2020 09:05 am ET
Benefits of Stereotaxis Robotic Technology in COVID-19 Patient Highlighted in Publication
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the European Heart Journal highlighting the benefits of Stereotaxis’ robotic technology in a...
Jun 22, 2020 09:05 am ET
Stereotaxis to be Added to the Russell 2000® and Russell 3000® Indexes
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the company will be added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. stock...
Jun 18, 2020 09:05 am ET
Stereotaxis to Present at Cowen 5th Annual FutureHealth Conference
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at the Cowen 5th Annual FutureHealth Conference on Thursday,...
Jun 10, 2020 09:00 am ET
Pioneering Efforts in TeleRobotic Surgery Focus of Webcast Symposium on June 20th
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the hosting of an Inaugural Symposium on Saturday, June 20, 2020 by live interactive webcast. This half-day...
Jun 02, 2020 09:00 am ET
Stereotaxis Robotic Technology Now Referenced In Over 400 Scientific Publications
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has reached a significant milestone of over 400 scientific publications now documenting the clinical...
May 26, 2020 09:00 am ET
Stereotaxis Announces $15 Million Common Stock Financing
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain funds managed by Consonance Capital...
May 05, 2020 09:00 am ET
Stereotaxis Reports 2020 First Quarter Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2020. “Despite the challenges and disruptions inflicted...
Apr 30, 2020 09:00 am ET
Stereotaxis to Report First Quarter 2020 Financial Results on May 5, 2020
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 first quarter on Tuesday, May 5, 2020 before the open of...
Mar 10, 2020 08:00 am ET
Stereotaxis Reports 2019 Full Year Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019. “The past year was...
Mar 06, 2020 08:05 am ET
Stereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis Robotic Magnetic Navigation System
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Genesis RMN® System for the...
Feb 26, 2020 04:06 pm ET
Stereotaxis to Present at Three Investor Conferences in March
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at three investor conferences in March 2020. Cowen and...
Feb 26, 2020 04:05 pm ET
Stereotaxis to Report Fourth Quarter and Full Year 2019 Financial Results on March 10, 2020
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 fourth quarter and full year ended December 31, 2019 on...
Jan 16, 2020 09:00 am ET
Stereotaxis to Ring the Opening Bell® of the New York Stock Exchange
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange on Tuesday,...
Dec 16, 2019 09:00 am ET
First Patients Treated in New Robotic Arrhythmia Care Program at Overland Park Regional Medical Center
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest Health—the largest healthcare system in the Kansas City region—has launched a new robotic...
Dec 04, 2019 09:00 am ET
Stereotaxis CEO to Present at the 12th Annual LD Micro Main Event Investor Conference
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th Annual LD Micro Main Event...
Nov 22, 2019 09:00 am ET
Stereotaxis CEO to Present at the 12th Annual BIOMEDevice San Jose Conference
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th annual BIOMEDevice San Jose...
Nov 14, 2019 08:00 am ET
Stereotaxis Reports 2019 Third Quarter Financial Results
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019. “The third quarter was highlighted by...
Nov 08, 2019 09:00 am ET
Stereotaxis and Catheter Precision Combine Robotic Navigation and Preoperative Arrhythmia Localization to Treat Cardiac Arrhythmias
Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation...
Nov 06, 2019 09:00 am ET
Stereotaxis to Report Third Quarter 2019 Financial Results on November 14, 2019
Stereotaxis, Inc. (NYSE American: STXS) the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 third quarter ended September 30, 2019 on...
Nov 05, 2019 09:00 am ET
Stereotaxis and inHEART Combine Robotic Precision and Advanced Preoperative 3D Mapping to Treat Cardiac Arrhythmias
Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Navigation technologies. inHEART...
Nov 01, 2019 09:00 am ET
Stereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias
Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treated with the integration of ADAS 3D’s advanced preoperative substrate mapping and Stereotaxis’ Robotic Magnetic Navigation...
Sep 16, 2019 05:00 pm ET
Stereotaxis Announces CFO Transition
Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019....
Sep 03, 2019 04:05 pm ET
Stereotaxis Announces Uplisting to NYSE American
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its common stock has been approved for listing on the NYSE American. The Company’s common stock will...
Aug 08, 2019 08:05 am ET
Stereotaxis Reports 2019 Second Quarter Financial Results
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurrently...
Aug 08, 2019 08:00 am ET
Stereotaxis Announces $25 Million Private Placement
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million...
Aug 07, 2019 04:05 pm ET
Stereotaxis to Report Second Quarter 2019 Financial Results on August 8, 2019
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 second quarter ended June 30, 2019 on Thursday,...
Jul 31, 2019 09:00 am ET
Society for Cardiac Robotic Navigation to Showcase Stereotaxis Clinical Value & Technology
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will participate in the Society for Cardiac Robotic Navigation’s 4th Annual Meeting, which will take...
Jun 18, 2019 09:00 am ET
Stereotaxis Announces the First Graduating Class of the Robotic Electrophysiology Fellows Program
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the first graduating class from its Robotic Electrophysiology Fellows Program. The Robotic...
May 29, 2019 09:00 am ET
Stereotaxis to Present at 9th Annual LD Micro Invitational
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 9th Annual LD...
May 09, 2019 08:04 am ET
Stereotaxis Announces Next Generation Robotic Magnetic Navigation System and Imaging System
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, introduced today Stereotaxis Genesis RMN, the next-generation robotic platform and a significant advancement in robotic...
May 09, 2019 08:02 am ET
Stereotaxis and Osypka Enter Strategic Collaboration to Advance Robotic Catheter Technology
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and Osypka AG, a pioneer in electrophysiology and leading manufacturer of interventional products, announced today a broad...
May 09, 2019 08:00 am ET
Stereotaxis Reports 2019 First Quarter Financial & Operational Results
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2019. In separate press releases issued concurrently...
Apr 29, 2019 09:00 am ET
Stereotaxis to Showcase Innovation and Technology at Heart Rhythm 2019 and Report First Quarter 2019 Financial Results on May 8-9, 2019
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will participate in and showcase its innovation initiatives at the 40th Annual Heart Rhythm...
Mar 15, 2019 04:30 pm ET
Stereotaxis to Highlight Latest Techniques for Performing Robotic Ablations at European Heart Rhythm Association Annual Congress March 17-19
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will be attending the European Heart Rhythm Association (EHRA) Annual Congress from March 17-19...
Mar 15, 2019 12:59 pm ET
Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures
Stereotaxis (OTCQX: STXS) and Acutus Medical today announced the first patients have been successfully treated utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems. The integrated technologies are cleared for use...
Mar 15, 2019 12:37 pm ET
Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures
ST. LOUIS and CARLSBAD, Calif., March 15, 2019 /PRNewswire/ -- Stereotaxis (OTCQX: STXS) and Acutus Medical today announced the first patients have been successfully treated utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems. The integrated technologies are cleared for use in Europe with additional regulatory clearances expected in the coming months.
Mar 12, 2019 09:00 am ET
Stereotaxis Reports 2018 Full Year Financial Results
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an extremely...
Mar 04, 2019 09:00 am ET
Stereotaxis to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 fourth quarter and full year ended December 31, 2018...
Feb 19, 2019 09:00 am ET
Stereotaxis to Participate in BTIG Healthcare Investor Conference
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to participate in the BTIG...
Jan 24, 2019 09:00 am ET
Stereotaxis Announces Partnership with Kansas City Heart Rhythm Institute to Bring New Treatment to Arrhythmia Patients
Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias announced today a partnership with Kansas City Heart Rhythm Institute to bring new and cutting-edge treatments to arrhythmia...
Nov 26, 2018 09:00 am ET
Stereotaxis to Present at the 11th Annual LD Micro Main Event Investor Conference
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 11th Annual LD...
Nov 12, 2018 09:00 am ET
Stereotaxis Reports 2018 Third Quarter Financial Results
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2018. “We continue to make meaningful...
Nov 02, 2018 10:56 am ET
Stereotaxis to Report Third Quarter 2018 Financial Results on November 12, 2018
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 third quarter ended September 30, 2018 on Monday,...
Sep 25, 2018 09:00 am ET
Stereotaxis to Present at OTCQX Virtual Investor Conference for Domestic Companies
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will present at the OTCQX Virtual Investor Conference for Domestic Companies. Management will...
Aug 07, 2018 09:00 am ET
Stereotaxis Reports 2018 Second Quarter Financial Results
Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2018. “The second quarter was notable for the...
Jul 31, 2018 09:00 am ET
Stereotaxis to Report Second Quarter 2018 Financial Results on August 7, 2018
Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 second quarter ended June 30, 2018 on Tuesday, August...
Jun 25, 2018 08:30 am ET
Stereotaxis and Johnson & Johnson’s Biosense Webster Extend Development Alliance and Supply Agreement
Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has entered into an amendment to the long-term Development Alliance and Supply Agreement with...
Jun 04, 2018 09:00 am ET
Stereotaxis Announces Changes to its Board of Directors
Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Ross B. Levin to its board of directors. Mr. Levin is the Director of Research at...
May 22, 2018 09:00 am ET
Stereotaxis to Present at 8th Annual LD Micro Invitational
Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 8th Annual LD...
May 14, 2018 09:00 am ET
Stereotaxis Reports 2018 First Quarter Financial Results
Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2018. “We continue to improve our commercial...
May 04, 2018 09:05 am ET
Stereotaxis to Highlight Unique Advantages of Robotic Cardiac Ablation at Heart Rhythm 2018
Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at the Boston...
May 04, 2018 09:00 am ET
Stereotaxis to Report First Quarter 2018 Financial Results on May 14, 2018
Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 first quarter ended March 31, 2018 on Monday, May 14,...
May 03, 2018 09:00 am ET
Stereotaxis and Acutus Medical Announce Strategic Collaboration
Stereotaxis (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and Acutus Medical, a global heart rhythm technology company transforming the way electrophysiologists map complex cardiac...
May 01, 2018 04:05 pm ET
Stereotaxis Announces Publication of Clinical Research Supplement Highlighting Robotic Navigation for Cardiac Arrhythmias
ST. LOUIS, May 01, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the Society for Cardiac Robotic Navigation (SCRN) has published a supplement...
Apr 11, 2018 09:00 am ET
Stereotaxis Announces Expanded European Labeling for Navigation in the Pericardial Space
ST. LOUIS, April 11, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that navigation in the pericardial space has been added to the CE...
Mar 06, 2018 09:01 am ET
Stereotaxis Reports 2017 Fourth Quarter and Full Year Financial Results
ST. LOUIS, March 06, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2017.
Mar 06, 2018 09:00 am ET
Stereotaxis Announces $10.0 Million Non-Dilutive Financing from Early Warrant Exercise
ST. LOUIS, March 06, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has raised $10.0 million in a non-dilutive financing through the...
Mar 02, 2018 09:00 am ET
Stereotaxis to Report Fourth Quarter and Full Year 2017 Financial Results on March 6, 2018
ST. LOUIS, March 02, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 fourth quarter and...
Feb 01, 2018 09:00 am ET
European Heart Rhythm Association Highlights Occupational Risk of Radiation Exposure in Electrophysiology Procedures
ST. LOUIS, Mo., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that the European Heart Rhythm Association (EHRA) has published a consensus...
Jan 08, 2018 09:00 am ET
Stereotaxis Reports Preliminary Fourth Quarter 2017 Revenue Results
ST. LOUIS, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced preliminary revenue results for the fourth quarter of 2017.
Dec 05, 2017 09:00 am ET
Stereotaxis Receives Regulatory Approval of e-Contact™ Module in Canada
First Procedures Performed at Toronto’s Sunnybrook Health Sciences Centre
Nov 20, 2017 09:00 am ET
Stereotaxis to Present at 29th Annual Piper Jaffray Healthcare Conference
ST. LOUIS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present...
Nov 09, 2017 09:00 am ET
Stereotaxis Reports Third Quarter 2017 Financial Results
ST. LOUIS, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2017.
Nov 02, 2017 09:00 am ET
Stereotaxis to Report Third Quarter 2017 Financial Results on November 9, 2017
ST. LOUIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 third quarter ended September 30, 2017 on Thursday, November 9, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments....
Nov 02, 2017 09:00 am ET
Stereotaxis to Report Third Quarter 2017 Financial Results on November 9, 2017
ST. LOUIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 third quarter ended...
Jul 11, 2017 09:00 am ET
Stereotaxis Receives Second Odyssey Vision™ System Orders from Two Leading Heart Hospitals
ST. LOUIS, July 11, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has secured second Odyssey Vision™ system orders from McLaren Bay Region Hospital in Michigan and Abrazo Arizona Heart Institute. Ranked among the top 10% in the nation for coronary interventional procedures by Healthgrades, McLaren Bay Region began utilizing the Odyssey Vision in September 2013. Arizona Heart Institute, a world-renowned destination for heart and vascular care, purchased its first O...
Apr 27, 2017 09:00 am ET
Stereotaxis to Report First Quarter 2017 Financial Results on May 8, 2017
ST. LOUIS, April 27, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 first quarter ended March 31, 2017 on Monday, May 8, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments....
Mar 07, 2017 09:00 am ET
Stereotaxis to Present at 29th Annual ROTH Conference
ST. LOUIS, March 07, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Acting Chief Executive Officer, is scheduled to present at the 29th Annual ROTH Conference. The conference is taking place March 12-15, 2017 in Dana Point, CA....
Feb 23, 2017 09:00 am ET
First Site in Japan to Install Stereotaxis Technology Completes 250 Procedures
ST. LOUIS, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc.  (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Takatsuki General Hospital, a leading acute care institution near Osaka, has completed 250 ablation procedures using the Company’s Niobe® ES remote magnetic navigation system. Takatsuki was the first hospital to order and install the Niobe system after the technology was released in Japan in 2013....
Nov 02, 2016 08:30 am ET
Stereotaxis to Report Third Quarter 2016 Financial Results on November 7, 2016
ST. LOUIS, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 third quarter ended September 30, 2016 on Monday, November 7, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments....
Oct 25, 2016 08:30 am ET
Robert Wood Johnson University Hospital Physician Surpasses 500 Procedures Using Stereotaxis Niobe® System
ST. LOUIS, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and Robert Wood Johnson University Hospital (RWJUH), a Cardiovascular Center of Excellence and the principal teaching hospital of the Rutgers Robert Wood Johnson Medical School, today announced that Dr. Zyad Younan has completed more than 500 cardiac ablation procedures using the Niobe® remote magnetic navigation system. Dr. Younan currently leads the Northeast region in catheter ablations performed using the Niobe system ...
Oct 18, 2016 08:30 am ET
Stereotaxis Technologies to be Highlighted at Society for Cardiac Robotic Navigation’s Inaugural Meeting in Amsterdam
ST. LOUIS, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its magnetic and robotic navigation systems will be represented at the inaugural meeting of the Society for Cardiac Robotic Navigation (SCRN) in Amsterdam, October 20 and 21. The meeting will bring together distinguished physicians experienced in the application of robotically navigated cardiac ablation to discuss, debate and educate on both the current role and future possibilities of robotics in clin...
Oct 13, 2016 08:30 am ET
Stereotaxis Awarded Patent in China for Vdrive® System with V-Loop™ Manipulator
ST. LOUIS, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the State Intellectual Property Office of the People’s Republic of China has awarded a patent protecting the Company’s Vdrive® robotic navigation system with V-Loop™ variable loop catheter manipulator. The patent is the second awarded to Stereotaxis in China for its Vdrive system and related disposable devices. The first patent covered the Company’s V-CAS™ and V-CAS Deflect™ catheter advancement system...
Sep 29, 2016 05:26 pm ET
Stereotaxis Completes Private Placement of $24 Million
ST. LOUIS, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has closed its previously announced private placement equity financing with a select group of institutional and other accredited investors, including both new and existing investors. The private placement consists of 24,000 shares of convertible preferred stock and warrants to purchase an aggregate of 36,923,077 shares of common stock for total gross proceeds of $24 million before expenses....
Sep 27, 2016 08:30 am ET
Stereotaxis Announces Multiple Positive Strategic Updates
- $24 Million Equity Investment -- Recruitment of Highly Experienced Board Members -- Retirement of Debt at Significant Discount -...
Aug 09, 2016 04:06 pm ET
Stereotaxis Completes Niobe® System Installation at Kakogawa Hospital
ST. LOUIS, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the launch of its Niobe® remote magnetic navigation system at Kakogawa Central City Hospital, which becomes the second of four systems shipped to Japan to have been installed. Opened July 1, Kakogawa Central City Hospital combines the former Kakogawa East City Hospital and Kakogawa West City Hospital into one 600-bed, state-of-the-art facility located approximately 280 miles southwest of Tokyo. On June 11 and 12, t...
Aug 09, 2016 04:05 pm ET
Stereotaxis Reports 2016 Second Quarter Financial Results
Ventricular tachycardia procedures increased 24% year over year, representing the 10th consecutive quarter of year-over-year volume growthThree Niobe® system installations completed, including the second installation in JapanEnhanced V-CAS Deflect™ catheter advancement system released in EuropeLowest first-half operating loss in Company historyConference call today at 4:30 p.m. Eastern Time ST. LOUIS, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today reported financial results for t...
Aug 04, 2016 08:00 am ET
OTC Markets Group Welcomes Stereotaxis, Inc. to OTCQX
NEW YORK, Aug. 4, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Stereotaxis, Inc. (OTCQX: STXS), a healthcare technology and innovation leader focused on the development of robotic cardiology instrument navigation systems, has qualified to trade on the OTCQX® Best Market.  Stereotaxis, Inc. previously traded on NASDAQ.
Aug 03, 2016 04:15 pm ET
Stereotaxis Common Stock to Begin Trading on OTCQX on August 4, 2016
ST. LOUIS, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that its shares of common stock will be eligible for trading on the OTCQX® Best Market, effective with the open of business on August 4, 2016....
Aug 02, 2016 09:00 am ET
Stereotaxis to Report Second Quarter 2016 Financial Results on August 9, 2016
ST. LOUIS, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 second quarter ended June 30, 2016 on Tuesday, August 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments....
Jul 26, 2016 09:00 am ET
Stereotaxis Releases Second Generation V-CAS Deflect™ System in Europe
ST. LOUIS, July 26, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the market release of its second generation V-CAS Deflect™ catheter advancement system in Europe. The V-CAS Deflect catheter advancement system is designed to remotely control a proprietary robotic deflectable sheath during a cardiac ablation procedure with the Stereotaxis Niobe® remote magnetic navigation system. The deflectable sheath provides improved support, stability and maneuverability of the magnetic ablat...
Jul 13, 2016 09:00 am ET
University of Chicago Medicine Creating High-Tech Arrhythmia Technology Suite with Stereotaxis Niobe® ES System
ST. LOUIS, July 13, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company’s Niobe® ES remote magnetic navigation system as part of its vision to create a cutting-edge arrhythmia technology suite. The University of Chicago Medicine is one of the nation's leading academic medical institutions, consistently ranked among the best hospitals in the nation by U.S. News & World Report. The Center for Arrhythmia Care at the Uni...
Jul 08, 2016 09:00 am ET
Stereotaxis Niobe® ES System Installed at Texas Children’s Hospital
ST. LOUIS, July 08, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that Texas Children’s Hospital in Houston has installed the Company’s Niobe® ES system, making it the only pediatric hospital in the country to offer the latest generation remote magnetic navigation platform for ablation procedures. Texas Children’s is recognized as one of the top children’s hospitals in the nation, ranked #2 nationally in cardiology and heart surgery by U.S. News & World Report....
Jun 14, 2016 09:00 am ET
Saint Alphonsus Physician Surpasses Procedure Milestone Using Stereotaxis Niobe® ES System
ST. LOUIS, June 14, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and Saint Alphonsus Health System in Idaho today announced that Dr. Margot Vloka has completed more than 500 cardiac ablation procedures using the Niobe® ES remote magnetic navigation system. Dr. Vloka is a board-certified clinical cardiac electrophysiologist (EP) at the Saint Alphonsus Stereotaxis lab and a Fellow of the Heart Rhythm Society....
Jun 07, 2016 09:00 am ET
Stereotaxis to Share its Latest Technology Advancements and Clinical Evidence at Cardiostim 2016 in Nice, France June 8-11
ST. LOUIS, June 07, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will share the latest innovations to its Niobe® ES magnetic navigation system and supporting clinical evidence at Cardiostim-EHRA Europace 2016, the 20th world congress in cardiac electrophysiology (EP) and cardiac techniques, taking place June 8-11 in Nice, France. The congress brings together more than 5,600 industry practitioners from over 125 countries to discuss the evolution of technologies and resea...
Jun 01, 2016 09:00 am ET
Paracelsus Medical University Clinical Study on Stereotaxis Technology Benefits Recognized at European Cardiac Arrhythmia Society Congress
ST. LOUIS, June 01, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a retrospective study conducted at Paracelsus Medical University in Nuremberg, Germany, which showed significantly reduced radiation exposure for patients undergoing catheter ablation for persistent atrial fibrillation (AF) with the Niobe® magnetic navigation system. The study received first place honors for “Best Poster Presentation” at the European Cardiac Arrhythmia Society Congress in Paris....
May 04, 2016 09:00 am ET
Stereotaxis to Highlight New Clinical Results and Automation Enhancements at Heart Rhythm 2016 in San Francisco May 4-7
ST. LOUIS, May 04, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2016 in San Francisco. During its 12th consecutive appearance at HRS, the Company will share results of recently published clinical studies, new technology enhancements, user experiences, and simulations of its computer-controlled mapping and lesion formation capabilities at Booth #1631....
May 02, 2016 09:00 am ET
Stereotaxis to Report First Quarter 2016 Financial Results on May 9, 2016
ST. LOUIS, May 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 first quarter ended March 31, 2016 on Monday, May 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments....
Apr 29, 2016 09:00 am ET
Stereotaxis Awarded U.S. Patent for Vmotion Spotlight Automation Feature of Vdrive® Robotic Navigation System
ST. LOUIS, April 29, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,314,222 titled, “Operation of a Remote Medical Navigation System Using Ultrasound Image.” The patent protects the current Spotlight feature of the Company’s Vmotion suite of automations, which enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE), or ultrasound, catheter to track a localized ablation cathet...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.